Displaying 1 - 1 of 1
| Active Ingredient | VORICONAZOLE |
| Therapeutic Class | AZOLES |
| Indications | Invasive aspergillosis in immunocompromised patients; candidaemia, in non-neutropenic patients, fluconazole-resistant serious invasive candidiasis, oesophageal candidiasis, and serious fungal infecti More ... |
| Caution | Visual disturbances, fever, rashes, nausea, vomiting, diarrhoea, abdominal pain, headache, sepsis, respiratory disorders, and peripheral oedema. |
| Dose Range |
IV: adults and adolescents: 6 mg/kg every 12 hours for the first 24 hours followed by maintenance dose of 4 mg/kg twice daily ; a lower dose of 3 mg/kg twice daily may be suitable for candidaemia in non- neutropenic patients or for deep tissue C |
| Drug Interactions | |
| Pregnancy | Because voriconazole can cause fetal harm, it should not be used during pregnanc More ... |
| Breast Feeding | It is not known whether voriconazole is distributed into milk. |